Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Acute-onset Herpes Zoster Pain

Interventions

DRUG

CNTX-2022 (lidocaine gel, 40%)

DRUG

Placebo

Trial Locations (1)

Nucleus Network, Melbourne